GOBLET CELL DYSFUNCTION IN ASTHMA

哮喘中的杯状细胞功能障碍

基本信息

  • 批准号:
    6476884
  • 负责人:
  • 金额:
    $ 21.61万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-12-07 至 2003-11-30
  • 项目状态:
    已结题

项目摘要

The mechanisms of mucus hypersecretion in asthma are poorly understood, even though sputum production is a prominent symptom of asthma exacerbations, and mucus plugging of the airways is prominent in the airways of patients who die from acute severe asthma. Although goblet cell hyperplasia is a pathologic feature of animal models of asthma, and allergen-induced goblet cell degranulation causes airway obstruction in sensitized animals, the role of the goblet cell in the pathogenesis of mucus hypersecretion and airway obstruction in human asthma is not clear. We hypothesize that the phenotype of the airway epithelium in mild and moderate asthma is characterized by goblet cell hypertrophy and hyperplasia, placing these patients at risk for acute episodes of airway obstruction secondary to an exaggerated goblet cell degranulation response to stimuli such as allergen and viruses. We further hypothesize that overexpression of mucin genes in airway goblet cells is one mechanism for goblet cell hypertrophy and hyperplasia. We propose to test our hypotheses using rigorous methods of quantitative morphometry, in situ hybridization, and RT-PCR to quantify goblet cell size, goblet cell degranulation, and goblet cell expression of mucin genes in endobronchial biopsies obtained during bronchoscopy from healthy and asthmatic subjects. In addition, because the effects of current asthma treatments on goblet cells are unknown, and because there is a need for studies of specific treatments of goblet cell hyperplasia, we propose to begin to explore the treatment of goblet cell abnormalities in human asthma by examining the effects of inhaled corticosteroids on goblet cell hypersecretion, goblet cell mucin secretion, and goblet cell mucin gene expression. Aim 1 will determine if mRNA levels for MUC-2 and MUC-5AC are higher than normal in goblet cells in the airway epithelium of asthmatic subjects. Aim 2 will determine if goblet cell degranulation occurs in asthmatic subjects following allergen challenge. Aim 3 will determine if treatment with an inhaled corticosteroid decreases mucin stores in goblet cells, mucin secreted on the airway epithelial surface, and mucin mRNA levels in endobronchial biopsies. The proposed studies address an unmet need, because few studies have been published focusing on goblet cells in human asthma. The application of the methods described here provide the opportunity to begin to understand the relationship between goblet cell hypersecretion and airway obstruction in human asthma, and may suggest strategies for improving treatment.
哮喘中粘液分泌过多的机制尚不清楚,

项目成果

期刊论文数量(13)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
"Reactive airways disease". A lazy term of uncertain meaning that should be abandoned.
“反应性气道疾病”。
Asthma: prevalence, pathogenesis, and prospects for novel therapies.
哮喘:患病率、发病机制和新疗法的前景。
  • DOI:
    10.1001/jama.286.4.395
  • 发表时间:
    2001
  • 期刊:
  • 影响因子:
    0
  • 作者:
    Woodruff,PG;Fahy,JV
  • 通讯作者:
    Fahy,JV
Epithelial desquamation in asthma: artifact or pathology?
哮喘中的上皮脱落:人为因素还是病理原因?
Allergen challenge causes inflammation but not goblet cell degranulation in asthmatic subjects.
过敏原激发会导致哮喘受试者炎症,但不会导致杯状细胞脱颗粒。
{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

John V Fahy其他文献

Development of an asthma health-care burden score as a measure of severity and predictor of remission in SARP III and U-BIOPRED: results from two major longitudinal asthma cohorts
开发哮喘保健负担评分作为 SARP III 和 U-BIOPRED 中严重程度的衡量指标和缓解预测因子:来自两个主要纵向哮喘队列的结果
  • DOI:
    10.1016/s2213-2600(24)00250-9
  • 发表时间:
    2025-01-01
  • 期刊:
  • 影响因子:
    32.800
  • 作者:
    Joe G Zein;Nazanin Zounemat-Kermani;Ian M Adcock;Bo Hu;Amy Attaway;Mario Castro;Sven-Erik Dahlén;Loren C Denlinger;Serpil C Erzurum;John V Fahy;Benjamin Gaston;Annette T Hastie;Elliot Israel;Nizar N Jarjour;Bruce D Levy;David T Mauger;Wendy Moore;Michael C Peters;Kaharu Sumino;Elizabeth Townsend;Eugene R Bleecker
  • 通讯作者:
    Eugene R Bleecker

John V Fahy的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('John V Fahy', 18)}}的其他基金

Evaluating the Impact of Metabolic Dysfunction on Asthma Pathology and Physiology
评估代谢功能障碍对哮喘病理学和生理学的影响
  • 批准号:
    10688260
  • 财政年份:
    2022
  • 资助金额:
    $ 21.61万
  • 项目类别:
Evaluating the Impact of Metabolic Dysfunction on Asthma Pathology and Physiology
评估代谢功能障碍对哮喘病理学和生理学的影响
  • 批准号:
    10503780
  • 财政年份:
    2022
  • 资助金额:
    $ 21.61万
  • 项目类别:
Sequential, Multiple Assignment, Randomized Trial in Severe Asthma Protocol (SMART-SA)
严重哮喘方案中的序贯、多重分配、随机试验 (SMART-SA)
  • 批准号:
    10454345
  • 财政年份:
    2017
  • 资助金额:
    $ 21.61万
  • 项目类别:
Sequential, Multiple Assignment, Randomized Trial in Severe Asthma Protocol (SMART-SA)
严重哮喘方案中的序贯、多重分配、随机试验 (SMART-SA)
  • 批准号:
    10221035
  • 财政年份:
    2017
  • 资助金额:
    $ 21.61万
  • 项目类别:
Sequential, Multiple Assignment, Randomized Trial in Severe Asthma Protocol (SMART-SA)
严重哮喘方案中的序贯、多重分配、随机试验 (SMART-SA)
  • 批准号:
    9751962
  • 财政年份:
    2017
  • 资助金额:
    $ 21.61万
  • 项目类别:
Carbohydrate-based Therapy for Lung Disease
以碳水化合物为基础的肺部疾病治疗
  • 批准号:
    9766888
  • 财政年份:
    2016
  • 资助金额:
    $ 21.61万
  • 项目类别:
A thiol-saccharide therapy to treat COVID-19
治疗 COVID-19 的硫醇糖疗法
  • 批准号:
    10226074
  • 财政年份:
    2016
  • 资助金额:
    $ 21.61万
  • 项目类别:
Carbohydrate-based Therapy for Lung Disease
以碳水化合物为基础的肺部疾病治疗
  • 批准号:
    10225939
  • 财政年份:
    2016
  • 资助金额:
    $ 21.61万
  • 项目类别:
Carbohydrate-based Therapy for Lung Disease
以碳水化合物为基础的肺部疾病治疗
  • 批准号:
    9147792
  • 财政年份:
    2016
  • 资助金额:
    $ 21.61万
  • 项目类别:
Epithelial cell reprogramming and mucus gel pathology in self-sustaining type 2 airway niches in asthma
哮喘自我维持型 2 型气道微环境中的上皮细胞重编程和粘液凝胶病理学
  • 批准号:
    10226878
  • 财政年份:
    2012
  • 资助金额:
    $ 21.61万
  • 项目类别:

相似海外基金

Defining new asthma phenotypes using high-dimensional data
使用高维数据定义新的哮喘表型
  • 批准号:
    2901112
  • 财政年份:
    2024
  • 资助金额:
    $ 21.61万
  • 项目类别:
    Studentship
Basophilic oncostatin M fuels nociceptor neuron-induced asthma
嗜碱性制瘤素 M 促进伤害感受器神经元诱发哮喘
  • 批准号:
    485504
  • 财政年份:
    2023
  • 资助金额:
    $ 21.61万
  • 项目类别:
    Salary Programs
Engaging Patient and Caregivers in Using Patient-reported Outcomes Measures in Pediatric Clinical Care for Asthma
让患者和护理人员参与儿科哮喘儿科临床护理中患者报告的结果测量
  • 批准号:
    495593
  • 财政年份:
    2023
  • 资助金额:
    $ 21.61万
  • 项目类别:
Air pollution and Asthma in Canada: Projections of burden and the value of climate adaptation strategies
加拿大的空气污染和哮喘:负担预测和气候适应战略的价值
  • 批准号:
    485322
  • 财政年份:
    2023
  • 资助金额:
    $ 21.61万
  • 项目类别:
    Operating Grants
Data-driven model links BMIz to gene expression in pediatric asthma
数据驱动模型将 BMIz 与小儿哮喘基因表达联系起来
  • 批准号:
    493135
  • 财政年份:
    2023
  • 资助金额:
    $ 21.61万
  • 项目类别:
BIOlogic drug safety and effectiveness interNational pharmacoepidemiologIC study in pregnant women with autoimmune disorders and asthma and their children (BIONIC)
患有自身免疫性疾病和哮喘的孕妇及其子女的生物药物安全性和有效性国际药物流行病学研究(BIONIC)
  • 批准号:
    493526
  • 财政年份:
    2023
  • 资助金额:
    $ 21.61万
  • 项目类别:
    Operating Grants
A Novel Approach to Target Neutrophilic Airway Inflammation and Airway Hyperresponsiveness in Therapy-Resistant (Refractory) Asthma.
一种针对难治性哮喘中性粒细胞性气道炎症和气道高反应性的新方法。
  • 批准号:
    10659658
  • 财政年份:
    2023
  • 资助金额:
    $ 21.61万
  • 项目类别:
Treating Maternal Depression in an Urban Community-Based Pediatric Asthma Clinic: Targeting Maternal Mood, Child Asthma Outcomes, and Health Disparities
在城市社区小儿哮喘诊所治疗孕产妇抑郁症:针对孕产妇情绪、儿童哮喘结果和健康差异
  • 批准号:
    10723233
  • 财政年份:
    2023
  • 资助金额:
    $ 21.61万
  • 项目类别:
Improving Prediction of Asthma-related Outcomes with Genetic Ancestry-informed Lung Function Equations
利用遗传祖先信息的肺功能方程改善哮喘相关结果的预测
  • 批准号:
    10723861
  • 财政年份:
    2023
  • 资助金额:
    $ 21.61万
  • 项目类别:
Prenatal Fatty Acid Supplementation and Early Childhood Asthma and Atopy in Black American Families
美国黑人家庭产前脂肪酸补充剂与儿童早期哮喘和特应性
  • 批准号:
    10586398
  • 财政年份:
    2023
  • 资助金额:
    $ 21.61万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了